MedTrace Logo

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

NCT05680155 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2025-09-10

No results posted yet for this study

Summary

The main purpose of this study is to investigate the efficacy and safety of XW003 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone

Conditions

Interventions

DRUG

Ecnoglutide

Subcutaneous Injection

DRUG

Placebo

Subcutaneous Injection with matched volume

Sponsors & Collaborators

  • Hangzhou Sciwind Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Dalong Zhu · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-29
Primary Completion
2024-06-12
Completion
2024-10-12

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05680155 on ClinicalTrials.gov